Similar articles for PMID: 27075380

Year	Number of Results
1993	1
2004	1
2005	1
2006	2
2009	1
2011	4
2012	18
2013	16
2014	21
2015	37
2016	17
2017	3
2018	4
2019	6
2020	4
2021	6
2022	6
2023	4
2024	0

1

How far down to push the LDL cholesterol? PCSK9 where statins fail.

Simko V, Ginter E. Simko V, et al. Bratisl Lek Listy. 2016;117(4):193-4. doi: 10.4149/bll_2016_036. Bratisl Lek Listy. 2016. PMID: 27075380 No abstract available.

2

[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].

Guijarro C, Ruilope LM. Guijarro C, et al. Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23. Med Clin (Barc). 2015. PMID: 26004275 Spanish. No abstract available.

3

Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.

Betteridge DJ. Betteridge DJ. Nat Rev Endocrinol. 2013 Feb;9(2):76-8. doi: 10.1038/nrendo.2012.254. Epub 2013 Jan 8. Nat Rev Endocrinol. 2013. PMID: 23296165 Review.

4

PCSK9 inhibition: the next statin?

Vogel RA. Vogel RA. J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31. J Am Coll Cardiol. 2012. PMID: 22465426 Free article. No abstract available.

5

[New drug development competition for LDL receptor].

Fujita T. Fujita T. Nihon Yakurigaku Zasshi. 2014 May;143(5):262. doi: 10.1254/fpj.143.262. Nihon Yakurigaku Zasshi. 2014. PMID: 24813799 Japanese. No abstract available.

6

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF. Sahebkar A, et al. Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.

7

Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Everett BM, Smith RJ, Hiatt WR. Everett BM, et al. N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7. N Engl J Med. 2015. PMID: 26444323 No abstract available.

8

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.

Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Koren MJ, et al. J Am Heart Assoc. 2015 Nov 19;4(11):e002224. doi: 10.1161/JAHA.115.002224. J Am Heart Assoc. 2015. PMID: 26586732 Free PMC article. Clinical Trial.

9

[Lipid control in high-risk patients: focus on PCSK9 inhibitors].

Filardi PP, Paolillo S, Trimarco B. Filardi PP, et al. G Ital Cardiol (Rome). 2015 Jan;16(1):44-51. doi: 10.1714/1776.19250. G Ital Cardiol (Rome). 2015. PMID: 25689751 Review. Italian.

10

[Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].

Christiansen MK, Jensen HK. Christiansen MK, et al. Ugeskr Laeger. 2015 Mar 9;177(11):V11140582. Ugeskr Laeger. 2015. PMID: 25786699 Free article. Review. Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

142 results

Results by year